Abstract

Diagnosis, prevention, management and treatment of acute and chronic medical conditions have improved with technological advancements in terms of scalability, efficacy, access, and personalized approach. Digital therapeutic applications (DTx) (Blue Star, Diabeo System, Livongo Diabetes Program, Tidepool etc.,) use web-based applications/cloud platforms to provide evidence-based, personalized, rapid point of care management of chronic, behavior-modifiable conditions, including diabetes mellitus (DM). DTx has improved patient compliance, therapeutic success and economic outcomes in DM management by enabling active patient engagement, lifestyle change, comprehensive medical care, and periodic monitoring of glycemic status. Addressing concerns along DTx data vulnerability, comparative efficacy with conventional treatments, ability to accommodate diverse population needs, and resolving ambiguous regulatory policies and reimbursement guidelines are critical for increasing access to DTx, and overcoming availability, accessibility, and affordability issues in the existing resource limited healthcare environment. In this commentary the authors explore the potential, prospects, and challenges of DTx in the management of Diabetes Mellitus.

摘要

随着可扩展性、有效性、可及性和个性化方法方面的技术进步，急性和慢性疾病的诊断、预防、管理和治疗得到了改善。数字治疗应用程序 (DTx)（Blue Star、Diabeo System、Livongo Diabetes Program、Tidepool 等）使用基于 Web 的应用程序/云平台来提供基于证据的、个性化的、快速的慢性、可改变行为的护理点管理，包括糖尿病 (DM)。DTx 通过实现积极的患者参与、生活方式的改变、全面的医疗护理和定期监测血糖状态，提高了 DM 管理中的患者依从性、治疗成功和经济结果。解决与 DTx 数据漏洞相关的问题，与传统治疗的比较疗效，满足不同人群需求的能力以及解决模棱两可的监管政策和报销指南对于增加 DTx 的可及性以及克服现有资源有限的医疗保健环境中的可用性、可及性和可负担性问题至关重要。在这篇评论中，作者探讨了 DTx 在糖尿病管理中的潜力、前景和挑战。